Stoke Therapeutics stock heads into November 3 results below key averages

Published on 10/05/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stoke Therapeutics stock was last at USD 25.62 on October 2, 2026, 17.8 percent below its 200-day average. Q2 revenue beat estimates, but GAAP EPS missed.

STOK, US86150R1077, Illustration mit AI erstellt.

Stoke Therapeutics stock (ISIN US86150R1077) was last at USD 25.62 on Nasdaq on October 2, 2026, down 1.5 percent for the session. The next scheduled report is November 3, 2026, giving the market a defined checkpoint after a quarter with higher revenue but a wider loss.

November 3 is the next checkpoint

According to EarningsToday, Stoke Therapeutics is scheduled to report on November 3, 2026. The company develops antisense oligonucleotide medicines for severe genetic diseases, with zorevunersen in clinical testing for Dravet syndrome, according to Stoke Therapeutics.

The November report will show whether the revenue profile can keep improving while clinical development costs remain elevated. That trade-off matters because the latest quarter combined commercial collaboration revenue with a substantial operating loss.

Quarterly loss sets the risk frame

For the quarter ended June 30, 2026, revenue reached USD 9.32 million, up 83.1 percent against the consensus estimate of USD 5.09 million, according to EarningsToday. GAAP EPS was negative USD 0.93 against consensus of negative USD 0.82, a 13.4 percent miss, while net loss totaled USD 61.62 million.

Consensus target stays elevated

According to InsiderTrades on October 3, 2026, 10 analysts rated the stock Buy and one rated it Sell, producing a Moderate Buy consensus and an average price target of USD 44.25. That target lies 72.7 percent above the October 2 price of USD 25.62, leaving the market focused on execution rather than on earnings alone.

Stock remains below key averages

STOK was last at USD 25.62 on Nasdaq on October 2, 2026, with a 52-week range of USD 20.32 to USD 40.22 and market capitalization of USD 1.7 billion. The price stood 17.8 percent below the 200-day average of USD 31.17, making the November report the next quantified test for the valuation gap.